Zota Health Care Ltd. (ZOTA) AI Stock Analysis

• Market Cap: ₹39.26B
• Dividend Yield: 0.08%
• Average Volume (3M): 158.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: 71.72%
• EPS Growth: -125.44%
• Country: IN
• Employees: 445
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -4.92
• Shares Outstanding: 29,463,516
• 10 Day Avg. Volume: 69,948
• 30 Day Avg. Volume: 158,967
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,359.00
• Price Target Upside: 1.99% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ₹1,359.00 ▲(1.99% Upside)

Zota Health Care Ltd.'s stock score is primarily impacted by its strong technical indicators, suggesting bullish momentum. However, significant financial performance challenges, including negative profitability and cash flow issues, weigh heavily on the overall score. The valuation metrics further highlight concerns with a negative P/E ratio and low dividend yield.

Zota Health Care Ltd. Business Overview & Revenue Model

Company Description

Zota Health Care Ltd. (ZOTA) is a leading pharmaceutical company based in India, primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. The company operates in various sectors including generic drugs, over-the-counter (OTC) products, and health and wellness products. Zota Health Care is known for its strong portfolio of products catering to diverse therapeutic categories, and its commitment to delivering affordable and quality healthcare solutions.

How the Company Makes Money

Zota Health Care Ltd. generates revenue through the sale of its pharmaceutical and healthcare products both domestically and internationally. The company's key revenue streams include the production and distribution of generic medications, which are typically sold to pharmacies, hospitals, and healthcare providers. Additionally, ZOTA earns income from the sale of OTC products directly to consumers. The company leverages its established distribution networks and strategic partnerships with distributors to expand its market reach. Furthermore, Zota Health Care's earnings are enhanced by its focus on innovation and product development, allowing it to introduce new and effective healthcare solutions that meet market demands.

Zota Health Care Ltd. Financial Statement Overview

Summary

Zota Health Care Ltd. demonstrates strong revenue growth but faces significant profitability and cash flow challenges. High leverage and negative profitability margins signal potential financial instability, requiring improved operational efficiency and cash flow management for sustainable growth.

Income Statement

Zota Health Care Ltd. has seen significant revenue growth from 2024 to 2025, with a revenue growth rate of 62.3%. However, the company is facing profitability challenges with a negative net profit margin of -19.2% and a gross profit margin of 53.1% in 2025. Negative EBIT and EBITDA margins further highlight operational inefficiencies, impacting overall profitability.

Balance Sheet

The company has a moderately high debt-to-equity ratio of 0.62, indicating reliance on debt financing. Despite this, the equity ratio is relatively stable at 50.9%, suggesting a balanced capital structure. Return on equity is negative, reflecting ongoing profitability issues. The company's asset base has grown, which could support future expansion if profitability improves.

Cash Flow

Negative free cash flow and operating cash flow indicate liquidity challenges, with a significant free cash flow decline from the previous year. The company has a negative free cash flow to net income ratio, suggesting cash generation issues. Financing activities have been used to support operations, raising concerns about sustainability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.93B	1.80B	1.40B	1.31B	1.07B
Gross Profit	1.56B	803.38M	310.68M	418.86M	193.14M
EBITDA	-36.65M	82.07M	98.05M	164.26M	28.63M
Net Income	-563.98M	-143.48M	-57.73M	89.08M	-2.09M
Balance Sheet
Total Assets	4.39B	2.28B	1.58B	1.39B	854.69M
Cash, Cash Equivalents and Short-Term Investments	36.19M	10.05M	11.15M	22.99M	13.46M
Total Debt	1.40B	952.85M	451.22M	149.00M	0.00
Total Liabilities	2.12B	1.38B	777.55M	494.67M	191.72M
Stockholders Equity	2.24B	899.77M	803.57M	896.27M	662.97M
Cash Flow
Free Cash Flow	-959.42M	-226.94M	-145.05M	100.84M	-28.18M
Operating Cash Flow	-499.64M	-59.84M	-20.06M	133.32M	-8.90M
Investing Cash Flow	-956.20M	-129.03M	147.03M	-266.52M	38.20M
Financing Cash Flow	1.45B	187.76M	-138.81M	142.73M	-24.19M

Zota Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1332.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZOTA, the sentiment is Positive. The current price of 1332.5 is above the 20-day moving average (MA) of 1210.37, above the 50-day MA of 1112.47, and above the 200-day MA of 888.76, indicating a bullish trend. The MACD of 32.41 indicates Positive momentum. The RSI at 71.56 is Negative, neither overbought nor oversold. The STOCH value of 49.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZOTA.

Zota Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALEMBICLTD	68 Neutral	₹27.86B	8.80		2.21%	28.84%	13.01%
SMSPHARMA	61 Neutral	₹20.42B	26.99		0.18%	10.29%	26.79%
ZOTA	54 Neutral	₹39.26B	―		0.08%	71.72%	-125.44%
SOLARA	53 Neutral	₹29.08B	126.42		―	-7.29%	―
Sector *	51 Neutral	$7.42B	-0.36	-40.86%	2.27%	22.89%	-2.16%
INDOCO	47 Neutral	₹26.90B	96.22		0.53%	-8.28%	-247.34%
PANACEABIO	44 Neutral	₹26.38B	―		―	-0.01%	-616.18%